drugset
drugset / Trial / NCT00832182

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

NCT00832182 ↗

Phase 3 Completed 75 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the long-term safety of insulin aspart in the management of type 1 diabetes. An extension to the ANA/DCD/065 trial

Timeline

Start
1999-12-22
Primary completion
2002-11-25
Completion
2002-11-25

Publications

  • Results Cada DJ, Levien T, Baker DE. Insulin aspart. Hospital Pharmacy 2000; 35: 1221-1229

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic — —
Background insulin NPH Protein / enzyme biologic — —

Indications

type 1 diabetes mellitus